An Introduction to Genitourinary Cancer
Genitourinary cancers incorporate the sub-specialities of prostate, kidney, bladder and testicular cancer. Advances in immunotherapies, targeted therapies and combination therapies have improved patient outcomes over recent years.
Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes, view our expert-led learning activities.
Our supporting partners do not constitute an endorsement of the content on this page.
Genitourinary Cancer Content
Is HER2 targeting on the horizon in urothelial carcinoma?
A GU oncologist shares insights into HER2 overexpression, testing and targeting in urothelial carcinoma.
- Discuss the clinical significance of HER2 expression in patients with urothelial carcinoma and considerations for molecular testing
- Evaluate emerging HER2-targeting treatment strategies for patients with urothelial carcinoma and the latest clinical evidence
ESMO 2023: Putting patients first – cultivating care in bladder cancer
Watch leading genitourinary cancer experts Prof. Petros Grivas, Dr Enrique Grande, and Prof. Viktor Grünwald discuss evidence supporting the use of avelumab as first-line maintenance therapy in advanced urothelial cancer (UC), the current treatment landscape and best practice, and approaches to optimising patient experiences and outcomes.
PSMA-targeted radiopharmaceuticals: An evolving approach to prostate cancer management
Three experts discuss data presented at ESMO 2023 on PSMA-targeted radiopharmaceuticals in prostate cancer.
- Describe potential strategies to refine selection of patients with advanced prostate cancer for treatment with PSMA-targeting radiopharmaceuticals
- Outline how the latest data for PSMA-targeting radiopharmaceuticals may impact the timing of their use in patients with advanced prostate cancer
- Analyse the latest data on radiopharmaceuticals in advanced prostate cancer, including combination strategies and novel agents in clinical development
Highlights in genitourinary cancers (non-prostate) – SunRISe-1, THOR-2, EV-302 CheckMate 901: Petros Grivas, ESMO 2023
ESMO 2023 brought forth some practice-changing data in the field of non-prostate genitourinary cancer. To understand these, as well as the other key trials and highlights from the meeting, we engaged in a conversation with the Clinical Director of the Genitourinary Cancer Program at the University of Washington and Fred Hutchinson Cancer Center, Prof. Petros […]
Top 5 tips for a successful career in medical oncology: Petros Grivas, ESMO 2023
As part the Young Oncologists session, at ESMO 2023, Prof. Petros Grivas (Clinical Director of the Genitourinary Cancer Program, University of Washington and Fred Hutchinson Cancer Center, Seattle, USA) and colleagues, spent time speaking with medial students and early-career physicians about developing a successful career in medial oncology. For those that were unable to attend the […]
ARPi vs. SOC and taxanes in mCRPC – ProBio study: Henrik Grönberg, EMSO 2023
The uniquely designed Prostate Biomarker (ProBio) study (NCT03903835) used outcome-adaptive randomization to compare biomarker-driven treatment selection against physician’s choice, and to compare androgen receptor inhibitors (ARPIs) against standard-of-care (SOC) and taxanes in castrate-resistant prostate cancer (mCRPC). To learn more about the trials unique design, the details surrounding the biomarker signatures investigated and the treatments compared, […]
Optimizing androgen deprivation therapy (ADT) in advanced prostate cancer
Watch three experts discuss the risks and benefits of ADT, the barriers to equitable care and how to improve treatment adherence in prostate cancer.
- Review the risks and benefits of gonadotropin-releasing hormone agonists and antagonists in the treatment of advanced prostate cancer
- Discuss strategies to promote equitable care and address disparities in prostate cancer treatment outcomes
- Evaluate ways to incorporate patient preferences and improve adherence to ADT in clinical practice
Adverse event identification and management in locally advanced/metastatic urothelial carcinoma
An oncologist, urologist and nurse discuss adverse event identification and management with immunotherapies and targeted therapies.
- Identify adverse events promptly in patients receiving immunotherapy or targeted therapy for locally advanced/metastatic urothelial carcinoma
- Use appropriate management strategies for the adverse events that arise in patients receiving immunotherapy or targeted therapy for locally advanced/metastatic urothelial carcinoma
- Apply a multidisciplinary approach to the identification and management of adverse events in patients receiving immunotherapy or targeted therapy for locally advanced/metastatic urothelial carcinoma
Looking to the future with Arnulf Stenzl: What can we hope to see in urological oncology in the next 5 years?
Secretary General of the European Association of Urology (EAU), Prof Arnulf Stenzl, discusses what he hopes to see in the field of uro-oncological surgery in the next five years. He hopes this will include improving early detection of prostate cancer and therefore the possibility of avoiding surgery; improving prognostic factors and diagnosis in early disease […]